share_log

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $15 Price Target

Benzinga ·  Mar 29, 2023 06:48

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment